Delirium, Hemodynamic Instability
Conditions
Keywords
Target Controlled Infusion
Brief summary
For patients requiring the heart valve replacement surgery, heart function is injured in different degree.Thus, minimizing the impact of the anesthesia drug on the cardiovascular system has important clinical meanings. Etomidate has slight effect on the cardiovascular system, often used in the induction of anesthesia, however target controlled infusion etomidate in maintenance of anesthesia is less used. So, the trial is designed to observe the application value of TCI etomidate in thoracoscopic mitral valve replacement surgery.
Interventions
The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\ 60.
The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\ 60.
BIS monitored from beginning of anesthesia induction to the end of the surgery.
Midazolam 0.03 mg/kg injection vein,Sufentanyl 0.5\ 1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
After the induction of anesthesia, Tracheal intubation is performed.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Age 18\ 75 years old 2. Selective cardiopulmonary bypass thoracoscopic mitral vales replacement surgery 3. Received heart surgery for the first time 4. New York Heart Association(NYHA) II\ III 5. Written informed consent -
Exclusion criteria
1. Emergency surgery 2. Anticipated survival time \<1 yrs 3. Serious heart, brain, liver,kidney,lung,endocrine diseases or serious infection 4. Prolonged use of hormone or history of adrenal suppression disease 5. Severe mediastinal fiber thickening or fibrous adhesions 6. Allergy to experimental drug or other contraindications 7. Occurred or expected occurring of difficulty airway 8. Sure or suspected narcotic analgesics abuse 9. History of neuro-muscular disease 10. Mental instability or metal disease 11. Pregnancy or brest-feeding 12. Participated other clinical trial past 30 days 13. Malignant hyperthermia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood pressure | from the beginning of induction to the surgery over, up to 6 hrs. | blood pressure(systolic blood pressure and diastolic blood pressure) is monitored and recorded at 9 time points, including 10 minutes before induction,the right moment after induction of anesthesia and tracheal intubation,the beginning of surgery and the cardiopulmonary bypass(CPB),the time the ascending aorta is blocked and unstuck,the time the CPB and the surgery is over. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Life quality | at the time of one month right after the surgery | using the Activities of Daily Living (ADL) to assess the life quality one month after the surgery. |
| Time of recovery from anesthesia | from the time TCI is stopped to the time patients' eyes open after the surgery, up to 30 minutes. | — |
| Bispectral index (BIS) value | from the beginning of induction to the surgery over, up to 6 hrs. | BIS is monitored and recorded at 9 time points, including 10 minutes before induction,the right moment after induction of anesthesia and tracheal intubation,the beginning of surgery and the cardiopulmonary bypass(CPB),the time the ascending aorta is blocked and unstuck,the time the CPB and the surgery is over. |
| onset time | The time from TCI etomidate or propofol to the disappearance of eyelash reflex,up to 10 minutes. | The time period from TCI etomidate or propofol to the disappearance of eyelash reflex. |
| Heart rate | from the beginning of induction to the surgery over, up to 6 hrs. | Heart rate is monitored and recorded at 9 time points, including 10 minutes before induction,the right moment after induction of anesthesia and tracheal intubation,the beginning of surgery and the cardiopulmonary bypass(CPB),the time the ascending aorta is blocked and unstuck,the time the CPB and the surgery is over. |
| Delirium | The right moment of patients'leaving off PACU, expected to be 2 h from the end the of operation | Using Confusion Assessment Method for the Intensive Care Unit(CAM-ICU) to screening of delirium. |
| Number of Participants with Serious and Non-Serious Adverse Events | Up to 1 month | Number of Participants with Serious and Non-Serious Adverse Events including major adverse cardiovascular and cerebrovascular event such as cardiac infraction,stroke, acute renal failure, re-surgery,and death. Safety Issue?: Yes |
Other
| Measure | Time frame | Description |
|---|---|---|
| Dosage of anesthesia drug | from the beginning of induction of anesthesia to the surgery over, up to 6 hrs. | record the dosage of the anesthesia drug including propofol and etomidate, sufentanyl and rocuronium used during the period of maintenance of anesthesia. |
| Respiratory rates(HR) | from the beginning of induction to the surgery over, up to 6 hrs. | Respiratory rate is monitored and recorded at 9 time points, including 10 minutes before induction,the right moment after induction of anesthesia and tracheal intubation,the beginning of surgery and the cardiopulmonary bypass(CPB),the time the ascending aorta is blocked and unstuck,the time the CPB and the surgery is over. |
| pulse blood oxygen saturation (SPO2) | from the beginning of induction to the surgery over, up to 6 hrs. | pulse blood oxygen saturation is monitored and recorded at 9 time points, including 10 minutes before induction,the right moment after induction of anesthesia and tracheal intubation,the beginning of surgery and the cardiopulmonary bypass(CPB),the time the ascending aorta is blocked and unstuck,the time the CPB and the surgery is over. |